FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026560392> ?p ?o ?g. }

• W3026560392 endingPage "S30" @default.
• W3026560392 startingPage "S30" @default.
• W3026560392 abstract "Recurrent/metastatic cervical cancer (rmCC) poses a significant clinical burden, particularly among women progressing after first-line therapy. Evidence is limited that second-line or later (2L+) treatment improves outcomes, particularly following treatment with the current first-line standard-of-care, bevacizumab in conjunction with paclitaxel-cisplatin or paclitaxel-topotecan. This systematic literature review investigated the efficacy of 2L+ treatments for rmCC. Systematic searches and study selection were undertaken per a predefined protocol. Eligible studies were prospective studies including >10 patients with squamous cell, adenocarcinoma or adenosquamous histologies receiving 2L+ treatments for rmCC published from 2003-March 2019. Eligible interventions were those recommended by NCCN or ESMO guidelines and outcomes included overall response rate (ORR), overall survival, and progression-free survival. Among 47,897 records screened, 13 studies met inclusion criteria; all were small, single-arm studies (for all except two studies, n≤35). Only two reported first-line bevacizumab use, one of which led to the accelerated approval of pembrolizumab and reported a 12.2% ORR in the overall population (comprising 84% PD-L1-positive patients). The remaining studies reflected time-frames prior to the approval of bevacizumab in first-line, reported limited efficacy with varying outcome definitions, and most responses were unconfirmed. Two studies investigated 2L+ combination therapies (bevacizumab/atezolizumab, veliparib/topotecan) and reported ORRs of 7-20%, with no complete responses. Eleven 2L+ monotherapy studies were identified, three reporting no responses and only one reporting complete responses. Of studies with partial responses, ORRs were between 4.5-15% (n=7 of 8 studies). One study reported a partial response rate of 29%, but excluded prior taxane use, reflecting a distinct patient population. Literature on the outcomes of 2L+ therapy in rmCC is limited and reflected small, single-arm studies, with only one conducted after the approval of bevacizumab in first-line. More data are needed to understand the place in therapy of current 2L+ regimens." @default.
• W3026560392 created "2020-05-29" @default.
• W3026560392 creator A5003504334 @default.
• W3026560392 creator A5027600192 @default.
• W3026560392 creator A5030492477 @default.
• W3026560392 creator A5034418475 @default.
• W3026560392 creator A5046470318 @default.
• W3026560392 creator A5081097047 @default.
• W3026560392 creator A5087320027 @default.
• W3026560392 date "2020-05-01" @default.
• W3026560392 modified "2023-09-30" @default.
• W3026560392 title "PCN43 SYSTEMATIC LITERATURE REVIEW OF THE EFFICACY OF SECOND-LINE OR LATER TREATMENTS FOR RECURRENT OR METASTATIC CERVICAL CANCER" @default.
• W3026560392 doi "https://doi.org/10.1016/j.jval.2020.04.1548" @default.
• W3026560392 hasPublicationYear "2020" @default.
• W3026560392 type Work @default.
• W3026560392 sameAs 3026560392 @default.
• W3026560392 citedByCount "0" @default.
• W3026560392 crossrefType "journal-article" @default.
• W3026560392 hasAuthorship W3026560392A5003504334 @default.
• W3026560392 hasAuthorship W3026560392A5027600192 @default.
• W3026560392 hasAuthorship W3026560392A5030492477 @default.
• W3026560392 hasAuthorship W3026560392A5034418475 @default.
• W3026560392 hasAuthorship W3026560392A5046470318 @default.
• W3026560392 hasAuthorship W3026560392A5081097047 @default.
• W3026560392 hasAuthorship W3026560392A5087320027 @default.
• W3026560392 hasBestOaLocation W30265603921 @default.
• W3026560392 hasConcept C121608353 @default.
• W3026560392 hasConcept C126322002 @default.
• W3026560392 hasConcept C141071460 @default.
• W3026560392 hasConcept C143998085 @default.
• W3026560392 hasConcept C2776694085 @default.
• W3026560392 hasConcept C2777802072 @default.
• W3026560392 hasConcept C2781209748 @default.
• W3026560392 hasConcept C2908647359 @default.
• W3026560392 hasConcept C535046627 @default.
• W3026560392 hasConcept C71924100 @default.
• W3026560392 hasConcept C99454951 @default.
• W3026560392 hasConceptScore W3026560392C121608353 @default.
• W3026560392 hasConceptScore W3026560392C126322002 @default.
• W3026560392 hasConceptScore W3026560392C141071460 @default.
• W3026560392 hasConceptScore W3026560392C143998085 @default.
• W3026560392 hasConceptScore W3026560392C2776694085 @default.
• W3026560392 hasConceptScore W3026560392C2777802072 @default.
• W3026560392 hasConceptScore W3026560392C2781209748 @default.
• W3026560392 hasConceptScore W3026560392C2908647359 @default.
• W3026560392 hasConceptScore W3026560392C535046627 @default.
• W3026560392 hasConceptScore W3026560392C71924100 @default.
• W3026560392 hasConceptScore W3026560392C99454951 @default.
• W3026560392 hasLocation W30265603921 @default.
• W3026560392 hasOpenAccess W3026560392 @default.
• W3026560392 hasPrimaryLocation W30265603921 @default.
• W3026560392 hasRelatedWork W2020038107 @default.
• W3026560392 hasRelatedWork W2028072220 @default.
• W3026560392 hasRelatedWork W2110506075 @default.
• W3026560392 hasRelatedWork W2165086348 @default.
• W3026560392 hasRelatedWork W2167750533 @default.
• W3026560392 hasRelatedWork W2170569142 @default.
• W3026560392 hasRelatedWork W2590783779 @default.
• W3026560392 hasRelatedWork W2610030900 @default.
• W3026560392 hasRelatedWork W2953910641 @default.
• W3026560392 hasRelatedWork W4247869942 @default.
• W3026560392 hasVolume "23" @default.
• W3026560392 isParatext "false" @default.
• W3026560392 isRetracted "false" @default.
• W3026560392 magId "3026560392" @default.
• W3026560392 workType "article" @default.